West Pharmaceutical Services, Inc. (NYSE:WST) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

Other equities research analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $114.00 price objective for the company in a research report on Friday, June 9th. Jefferies Group LLC restated a “hold” rating and set a $90.00 price objective on shares of West Pharmaceutical Services in a research report on Thursday, June 8th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $90.18.

West Pharmaceutical Services (WST) traded down 0.44% during trading on Thursday, hitting $92.26. The company had a trading volume of 3,065,014 shares. The stock has a market capitalization of $6.79 billion, a PE ratio of 38.19 and a beta of 1.12. West Pharmaceutical Services has a one year low of $70.17 and a one year high of $99.91. The stock has a 50-day moving average of $95.25 and a 200-day moving average of $88.64.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a net margin of 11.88% and a return on equity of 14.89%. The business had revenue of $397.60 million during the quarter, compared to the consensus estimate of $406 million. During the same period last year, the business posted $0.59 EPS. West Pharmaceutical Services’s revenue was up 2.5% on a year-over-year basis. On average, equities analysts anticipate that West Pharmaceutical Services will post $2.73 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/27/west-pharmaceutical-services-inc-wst-downgraded-by-bidaskclub.html.

In other news, VP Daniel Malone sold 4,124 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, May 2nd. The shares were sold at an average price of $93.31, for a total value of $384,810.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO William J. Federici sold 54,996 shares of West Pharmaceutical Services stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $95.45, for a total transaction of $5,249,368.20. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can increased its stake in West Pharmaceutical Services by 1.2% in the second quarter. Great West Life Assurance Co. Can now owns 43,619 shares of the medical instruments supplier’s stock worth $4,120,000 after buying an additional 510 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in West Pharmaceutical Services by 12.4% in the second quarter. Janney Montgomery Scott LLC now owns 3,023 shares of the medical instruments supplier’s stock worth $286,000 after buying an additional 333 shares during the last quarter. Public Employees Retirement Association of Colorado increased its stake in West Pharmaceutical Services by 10.0% in the second quarter. Public Employees Retirement Association of Colorado now owns 230,195 shares of the medical instruments supplier’s stock worth $21,758,000 after buying an additional 20,927 shares during the last quarter. ING Groep NV acquired a new stake in West Pharmaceutical Services during the second quarter worth $846,000. Finally, Russell Investments Group Ltd. increased its stake in West Pharmaceutical Services by 66.9% in the second quarter. Russell Investments Group Ltd. now owns 14,028 shares of the medical instruments supplier’s stock worth $1,326,000 after buying an additional 5,625 shares during the last quarter. Institutional investors own 91.34% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.